Patents by Inventor Alexandre Harari

Alexandre Harari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230009041
    Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
    Type: Application
    Filed: April 28, 2022
    Publication date: January 12, 2023
    Applicants: Arizona Board of Regents, a body corporate of the State of Arizona acting for and on behalf of, Consejo Superior De Investigaciones Cientificas, IPPOX Foundation
    Inventors: Giuseppe Pantaleo, Thierry Calandra, Alexandre Harari, Thierry Roger, Mariano Esteban, Bertram Jacobs, Karen Kibler, Cornelius Melief, Rafick-Pierre Sekaly, Elias Haddad, James Tartaglia
  • Patent number: 11345928
    Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: May 31, 2022
    Assignees: Arizona Board of Regents, Conseju Superior De Investigaciones Cientificas, IPPOX Foundation
    Inventors: Giuseppe Pantaleo, Thierry Calandra, Alexandre Harari, Thierry Roger, Mariano Esteban, Bertram Jacobs, Karen Kibler, Cornelius Melief, Rafick-Pierre Sekaly, Elias El Haddad, James Tartaglia
  • Publication number: 20200338125
    Abstract: The invention relates to a method for expanding antigen-specific lymphocytes by culturing samples from a subject containing lymphocytes or lymphocytes derived from the sample in the presence of one or more peptides comprising antigens and/or in the presence of an antigen presenting cell presenting antigens. Also disclosed is the use of such method for improving personalized immunotherapy (e.g., tumor immunotherapy).
    Type: Application
    Filed: November 6, 2018
    Publication date: October 29, 2020
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
    Inventors: Sara BOBISSE, Alexandre HARARI, George COUKOS
  • Publication number: 20200172926
    Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
    Type: Application
    Filed: July 17, 2019
    Publication date: June 4, 2020
    Applicants: Arizona Board of Regents, a body corporate of the State of Arizona acting for and on behalf of Arizo, Consejo Superior De Investigaciones Cientificas, IPPOX Foundation
    Inventors: Giuseppe Pantaleo, Thierry Calandra, Alexandre Harari, Thierry Roger, Mario Esteban, Bertram Jacobs, Karen Kibler, Cornelius Melief, Rafick-Pierre Sekaly, Elias El Haddad, James Tartaglia
  • Patent number: 10370679
    Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: August 6, 2019
    Assignees: ARIZONA BOARD OF REGENTS, a body corporate of the State of Arizona acting for and on behalf of Ariz, CONSEJO SUPERIOR DE INVESTGACIONES CIENTRIFICAS, IPPOX FOUNDATION
    Inventors: Giuseppe Pantaleo, Thierry Calandra, Alexandre Harari, Thierry Roger, Mariano Esteban, Bertram Jacobs, Karen Kibler, Cornelius Melief, Rafick-Pierre Sekaly, Elias El Haddad, James Tartaglia
  • Publication number: 20170246280
    Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
    Type: Application
    Filed: October 10, 2016
    Publication date: August 31, 2017
    Inventors: Giuseppe Pantaleo, Thierry Calandra, Alexandre Harari, Thierry Roger, Mario Esteban, Bertram Jacobs, Karen Kibler, Cornelius Melief, Rafick-Pierre Sekaly, Elias Haddad, James Tartaglia
  • Patent number: 9670506
    Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: June 6, 2017
    Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, ACADEMISCH ZIKENHUIS LEIDEN, CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS, UNIVERSITE DE MONTREAL, ARIZONA BOARD OF REGENTS, SANOFI PASTEUR LIMITED
    Inventors: Giuseppe Pantaleo, Thierry Calandra, Alexandre Harari, Thierry Roger, Mariano Esteban, Bertram Jacobs, Karen Kibler, Cornelius Melief, Rafick-Pierre Sekaly, Elias Haddad, James Tartaglia
  • Patent number: 9146236
    Abstract: This disclosure relates to methods for differentiating between mammals having active and latent Tuberculosis disease, by determining the percentage of polyfunctional CD4+ T-cells expressing TNF-alpha, IFN-gamma, and IL-2, or by determining expression of IL-17.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: September 29, 2015
    Inventors: Giuseppe Pantaleo, Alexandre Harari, Matthieu Perreau
  • Publication number: 20130338059
    Abstract: This disclosure relates to methods for differentiating between mammals having active and latent Tuberculosis disease, by determining the percentage of polyfunctional CD4+ T-cells expressing TNF-alpha, IFN-gamma, and IL-2, or by determining expression of IL-17.
    Type: Application
    Filed: December 22, 2011
    Publication date: December 19, 2013
    Applicant: Centre Hospitalier Universitaire Vaudois
    Inventors: Giuseppe Pantaleo, Alexandre Harari, Matthieu Perreau
  • Publication number: 20120328653
    Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
    Type: Application
    Filed: April 29, 2010
    Publication date: December 27, 2012
    Inventors: Giuseppe Pantaleo, Thierry Calandra, Alexandre Harari, Thierry Roger, Mariano Esteban, Bertram Jacobs, Karen Kibler, Cornelius Melief, Rafick-Pierre Sekaly, Elias Haddad, James Tartaglia